| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 7.6 | 10.5 |
| Gross profit | 4.3 | 9.3 |
| Profit before tax | -11.4 | 1.5 |
| Net income | -11.4 | 0.8 |
| EPS (diluted, $ a share) | $-0.64 | $0.03 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -27.0% |
|---|---|
| Gross margin | 56.2% |
| Operating margin | -127.9% |
10-Q filed with the SEC, NASDAQ: BSEM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
BioStem Technologies, Inc.: key numbers
- Share price
- $0.9601Close, Nov 16
- Market cap
- $18.4M
- Shares outstanding
- 19.18MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from BioStem Technologies, Inc.
All →BioStem Technologies Earnings Call: Key Takeaways
BioStem is undergoing a high-stakes transition, prioritizing a $10-$12 million cost reduction and in-house manufacturing to offset significant Q3 losses and a dwindling cash position.
BioStem Technologies Financial Results
BioStem Technologies reported Q3 2026 financial results, highlighting sequential hospital revenue growth to $6.8 million and increased customer penetration. The company raised its full-year 2026 revenue guidance and is finalizing a cost reduction plan to reduce annualized cash operating expenses by $10-$12 million.
- Term
- Q3 2026
“We grew hospital revenue again this quarter, and importantly, are doing so by adding new accounts and increasing penetration with existing customers. The number of customers buying two or more of our product lines grew 14% from the second quarter. We also completed the final step of our commercial infrastructure build-out, and with in-house production of Neox and Clarix expected to begin in the first half of 2027, we are on track to become a fully vertically integrated company with those product lines.”
Jason Matuszewski, Chair and CEO of BioStem
“With these foundations in place, we are focused on strengthening the balance sheet, raising our gross margin, reducing operating expenses and narrowing our adjusted EBITDA loss as we work toward breakeven.”
Jason Matuszewski, Chair and CEO of BioStem
BioStem Technologies Capital Raise of $3M
BioStem Technologies entered into a securities purchase agreement with institutional investors for a $3.0 million private placement of 735,296 shares of common stock. The offering includes Series A and Series B warrants to purchase additional shares at an exercise price of $3.83 per share, which could provide an additional $5.6 million if fully exercised. Proceeds are intended for working capital and general corporate purposes.
- Value
- $3M
- Counterparty
- institutional investors
BioStem Technologies Other 8-K Filing
BioStem Technologies entered into a $40 million committed equity facility with Roth Principal Investments, allowing the company to sell shares of common stock at its discretion over a 36-month period. The facility provides opportunistic access to capital for working capital and general corporate purposes, though no shares were sold at the time of the filing. Sales are subject to a registration statement being declared effective and a minimum threshold price of $1.00 per share.
- Counterparty
- Roth Principal Investments, LLC
- Term
- 36 months